Clinical Trials

AI is already reshaping the clinical trials industry and that transformation looks set to continue over the next five years. New technologies will enable the development of more personalized medicines, empower more responsive trial designs and improve informed decision making by unlocking new data insights. read more

Much like the literal moonshots now back on the launch calendar, first in human studies are defined by the tension between danger and possibility. They are where bold ideas either earn the right to move forward or are stopped before they can do more harm than good. As an industry, our challenge is to keep reaching for those transformative rewards while taking the risks - scientific, financial, and human - every bit as seriously as a crew strapping in for a flight around the Moon. read more

In today’s highly connected healthcare ecosystem, wearable technology and electronic Clinical Outcome Assessments (eCOA) are converging to create new and unique opportunities for patient empowerment while at the same time driving the evolution of clinical research and treatment protocols. Patients are no longer bystanders - passive recipients of care – but engaged and active participants in their own therapeutic journeys. read more

There is no doubt Artificial Intelligence (AI) is having tangible benefits across the entire pharmaceutical chain. But there is also often a lack of clarity around AI. This can lead to an overestimation of potential impacts and underestimation of the complexities of implementation. read more

ICON has announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle, expanding the company’s digital innovation and AI strategy through its secure agentic platform, Orbis. read more

Phanes Therapeutics has expanded its clinical trial collaboration and supply agreement with Merck to evaluate spevatamig in combination with KEYTRUDA (pembrolizumab) and chemotherapy as a first-line treatment for biliary tract cancer (BTC). read more